American Society of Hematology

SHERPA: Blue

People

  1. Seshan
    Seshan
  2. Zelenetz
    Zelenetz
  3. Batlevi
    Batlevi
  4. Dogan
    Dogan
  5. Matasar
    Matasar
  6. Owens
    Owens
  7. Grieve
    Grieve
  8. Hamilton
    Hamilton
  9. Joffe
    Joffe
  10. Kumar
    Kumar

Groups

  1. Center for Hematologic Malignancies (9)
  2. Center for Pancreatic Cancer Research (9)
  3. Department of Medicine (9)
  4. Hematologic Malignancies, Division of (9)
  5. Biostatistics Service (8)
  6. Epidemiology and Biostatistics (8)
  7. Executive Committee, Center for Hematologic Malignancies (7)
  8. GSK Faculty (7)
  9. Lymphoma (6)
  10. Sloan Kettering Institute Postdocs (6)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "2021"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (9)
  2. Center for Pancreatic Cancer Research (9)
  3. Department of Medicine (9)
  4. Hematologic Malignancies, Division of (9)
  5. Biostatistics Service (8)
  6. Epidemiology and Biostatistics (8)

More Groups

People
  1. Venkatraman Seshan (6)
  2. Andrew Zelenetz (5)
  3. Ahmet Dogan (4)
  4. Colette Owens (4)
  5. Connie Batlevi (4)
  6. Matthew Matasar (4)

More People

Years
  1. 2021 (9)
Publications
  1. Blood (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The BMP/SMAD pathway is a key mediator of leukemic transformation of TP53-mutant post-MPN AML
    Meeting Abstract

    Li, B.; An, W.; Wang, H.; Krishnan, A.; Mowla, S.; Baslan, T.; Koche, R.; Xiao, W.; Lowe, S.; Levine, R. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J. R.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Copley, D.; Grieve, C.; Jacob, A. P.; Joseph, A.; Laraque, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
    Journal Article

    Dunbar, A.; Bolton, K. L.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J.; Kelly, D.; Farina, M.; Cordner, K. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition
    Journal Article

    Bala Tannan, N.; Manzari, M. T.; Herviou, L.; Da Silva Ferreira, M.; Hagen, C.; Kiguchi, H.; Manova-Todorova, K.; Seshan, V.; de Stanchina, E.; Heller, D. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save